|02-12-2019 12:12 PM CET - Health & Medicine||
Immuno-Oncology Market to grow at a CAGR of 21.5% by 2025| Industry Trends, Segment Analysis, Market Share Insights, Competitive Benchmarking, Regional Outlook | Industry participants: Bristol-Myers Squibb, Merck, AstraZeneca, Pfizer Inc. and others.
Press release from: Polaris Market Research & Consulting
The Global Immuno-Oncology Market Size was estimated to at USD 8,333.0 billion in 2017. Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.
Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses.
Request for sample pages of Immuno Oncology (I-O) Market Analysis: bit.ly/2DuztVt
The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.
The global immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures.
Moreover, rising number of ablations centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.
The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.
On the basis of treatment type, the global immuno-oncology market is segmented into Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines. Checkpoint inhibitors were the largest treatment process segment in 2017 that accounted for 54.7% of the overall revenue. On the basis of novel targets, the global market is segmented into IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i. VEGFi was the largest novel target segment that was used for immuno-oncology treatment processes in 2017 with a total market share of 11.2%. on the basis of cancer type, the global immuno-oncology Market is segmented into Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head, face & Neck Cancer, Bladder Cancer, Classical Hodgkin’s Lymphoma, Merkel Cell, and carcinoma. Revenue share of immuno-oncology treatment for classical hodgkin’s lymphoma was the largest in 2017 i.e. 15.31% among the listed tumor types in the report.
Browse report summary of Immuno Oncology (I-O) Market Analysis: bit.ly/2E4YRTc
On the basis of geography, North America was the largest regional market in 2017. High levels of spending on cancer treatments, also U.S. being one of the major country y with a huge population of cancer affected people on a global scale, the country being the host to the development of this technology, higher frequency of innovations of immuno oncology treatments or processes in the region specially in the U.S. etc., all of these factors have driven significant investment and alongside the demand for IO in the region. These factors have driven the North American market since the inception of this technology and over the forecast period it is expected to increase further.
Immuno-Oncology by Treatment Approaches
• Monoclonal Antibodies
• Therapeutic Vaccines
• Checkpoint Inhibitors
Immuno-Oncology by Novel Targets
• LAG-3 CPI
• oncolytic virus
• STING agonist
• TLR agonist
• GITR agonist
• TGF-b trap
• A2AR antagonist/CD73i
Immuno-Oncology by Tumor Types
• Non-Small Cell Lung Cancer,
• Renal Cell Carcinoma,
• Head & Neck Cancer,
• Bladder Cancer,
• Classical Hodgkin’s Lymphoma
• Merkel Cell Carcinoma
Immuno-Oncology by Regions
• North America [U.S., Canada, Mexico]
• Europe [Germany, UK, France]
• Asia-Pacific [China, India, Japan, Rest of Asia-Pacific]
• Latin America [ Brazil, Mexico]
• Middle East and Africa
Some of the key players operating in global immuno-oncology market:
• Bristol Myers Squibb
• Roche Holding AG
• Pfizer Inc.
• Incyte Corporation
Make an inquiry before buying of Immuno Oncology (I-O) Market Analysis: bit.ly/2I9po5E
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.
Corporate Sales, USA
Polaris Market Research
This release was published on openPR.
News-ID: 1580500 • Views: 146More releases